Department of Medical Microbiology and Immunology, and the M.I.N.D. Institute, University of California at Davis, CA, United States.
J Neuroimmunol. 2011 Mar;232(1-2):196-9. doi: 10.1016/j.jneuroim.2010.10.025. Epub 2010 Nov 20.
A role for immune dysfunction has been suggested in autism spectrum disorders (ASD). Elevated levels of chemokines have been detected in the brain and CSF of individuals with ASD but, to date, no study has examined chemokine levels in the plasma of children with this disorder. In the current study, we determined whether there were differential profiles of chemokines in the plasma of children with ASD compared to age-matched typically developing controls and children with developmental disabilities other than ASD. Increased MCP-1, RANTES and eotaxin levels were observed in ASD children compared with both control groups (p<0.03), and increased chemokine production was associated with higher aberrant behavior scores and more impaired developmental and adaptive function.. Elevated MCP-1, RANTES and eotaxin in some ASD children and their association with more impaired behaviors may have etiological significance. Chemokines and their receptors might provide unique targets for future therapies in ASD.
免疫功能障碍在自闭症谱系障碍(ASD)中起作用。在 ASD 患者的大脑和脑脊液中检测到趋化因子水平升高,但迄今为止,尚无研究检查该疾病患儿血浆中的趋化因子水平。在目前的研究中,我们确定了 ASD 患儿的血浆中趋化因子是否存在与年龄匹配的正常发育对照组和除 ASD 以外的发育障碍儿童不同的特征。与两个对照组相比,ASD 患儿的 MCP-1、RANTES 和 eotaxin 水平升高(p<0.03),趋化因子的产生增加与更高的异常行为评分以及更严重的发育和适应功能障碍有关。一些 ASD 患儿中升高的 MCP-1、RANTES 和 eotaxin 及其与更严重行为的关联可能具有病因学意义。趋化因子及其受体可能为 ASD 的未来治疗提供独特的靶标。